Strategic focus Target early-stage life sciences and university-affiliated spinouts in the Texas Medical Center ecosystem to accelerate commercialization partnerships and co-found new ventures, leveraging Fannin’s apprenticeship and seed-capital model.

Funding leverage Capitalize on ongoing SBIR/NIH grant activity tied to portfolio companies to identify co-investment and grant-support opportunities, offering tailored funding guidance and bridge financing to accelerate product development.

Portfolio growth Opportunity to scale partnerships as Fannin plans to add 15-20 portfolio companies in 3–5 years, presenting a steady stream of potential collaboration deals in therapeutics, diagnostics, and medical devices.

Strategic hires Leverage recent leadership additions and senior hires to position Fannin as a gateway for industry collaborations, licensing discussions, and joint development agreements with larger biotech and pharma players.

Proven exits & co-development Highlight past co-development success and notable investments to build credibility with potential partners seeking shared risk in early-stage programs, including opportunities aligned with Pulmotect and Allterum Therapeutics pipelines.